Non-small cell lung cancer
Conditions
Interventions
Grouping based on different adjuvant therapy methods:None
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Obtain the patient's written informed consent; (2) Male or female, age=18 years old; (3) The pathological stage is stage I NSCLC, and the primary tumor lesion is completely removed by surgery; (4) Contains at least one high-risk factor for recurrence (pathology: low-differentiated tumor/vascular invasion/visceral pleural invasion/pathological subtype with micronipple or solid components/air cavity spread; detection: blood MRD positive 1 month after surgery); (5) EGFR sensitive mutation is positive (19del and/or L858R mutation, with or without T790M mutation), and must be confirmed by tumor tissue analysis.
Exclusion criteria
Exclusion criteria: (1) Patients who have participated in any other anti-tumor clinical research at present or in the past; (2) Any previous NSCLC treatment with systemic anti-cancer therapy as the main treatment method, including cytotoxic therapy, targeted therapy (including tyrosine kinase inhibitors or monoclonal antibodies) and immunotherapy; (3) Patients who received adjuvant treatment before joining the group; (4) The researchers evaluate patients who are not suitable for the group, such as neurological disorders or metabolic disorders, physical examinations or laboratory tests suspected to have possible diseases, or contraindications to the use of research drugs, or high risk of treatment-related complications, etc.; (5) Have a history of other malignant tumors, or have now combined with other malignant tumors (except for malignant tumors that have been radically treated and have not recured for 5 years after surgery, such as cervical cancer in situ, skin basal cell carcinoma and thyroid papillary carcinoma, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Median survival;2/3/5-year disease-free survival;2/3/5-year overall survival;Safety; | — |
Countries
China
Contacts
Public ContactWei Liu
The First Hospital of Jilin University
Outcome results
None listed